Aduro Biotech (ADRO) Stock Price, News & Analysis

Company Overview

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $2.28 to $14.60
• 52-Week Range: N/A
• Volume: 171,500 shs
• Average Volume: 162,237 shs
• Market Capitalization: $236.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADRO Stock Analysis - Frequently Asked Questions

How were Aduro Biotech's earnings last quarter?

Aduro Biotech, Inc. (NASDAQ:ADRO) announced its quarterly earnings data on Monday, May, 4th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to the consensus estimate of $8.81 million. Aduro Biotech had a negative trailing twelve-month return on equity of 101.73% and a negative net margin of 230.92%.

When did Aduro Biotech IPO?

Aduro Biotech (ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What other stocks do shareholders of Aduro Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

• Last Earnings: 5/04/2020
• Today: 7/20/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ADRO
• CIK: 1435049
• Web: www.aduro.com
• Phone: (206) 485-7051
• Fax: N/A
• Employees: 152
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($5.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.37 million
• Net Margins: -230.92%
• Pretax Margin: N/A
• Return on Equity: -101.73%
• Return on Assets: -22.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.91
• Quick Ratio: 8.91

Sales & Book Value

• Annual Sales: $17.26 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.07 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 16,212,000
• Free Float: N/A
• Market Cap: $236.61 million
• Optionable: Optionable
• Beta: 0.40